Integrating AI into the electronic medical record can make patient data more usable and dependable for end-users, according to a review of the relevant scientific literature published this month in the American Journal of Clinical and Medical Research.
The Drug Enforcement Administration is proposing the adoption of some COVID-era prescription practices around certain controlled substances. The agency published a framework to guide any such changes Jan. 17.
Stephen Browning, the FDA's assistant director of hemodynamics and heart failure diagnostics, spoke with Cardiovascular Business about the agency's perspective on AI-enabled cardiovascular devices and many other topics.
Melissa Hubbard says her gynecologist and surgeon decided to remove her ovaries during a colectomy but failed to inform her of their intent. The case’s fate is now in the hands of the Wisconsin Supreme Court.
The agencies said private equity firms are rolling up healthcare sectors through serialized purchases that fly under the radar of regulators, creating an unsustainable level of consolidation.
The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.
HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.
Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.
